Phase 1b Trial of BGJ398/BYL719 in Solid Tumors

Launched by NOVARTIS PHARMACEUTICALS · Aug 21, 2013

Keywords

ClinConnect Summary

This dose escalation/dose expansion study will evaluate the combination of orally administered BGJ398 in combination with orally administered BYL719. During the dose escalation part, the MTD of the combination will be determined in patients whose advanced or metastatic tumors express mutations to PIK3CA. Once the MTD has been determined, the expansion part will begin. Patients will be addd to one of three arms based on the disease type and genetic changes. Patients with metastatic colorectal cancer are not eligible for participation in the expansion part.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Histologically/cytologically confirmed advanced or metastatic solid tumors who have failed standard therapy or for whom no effective standard anti-cancer therapy exists
• • Documented PIK3CA mutations in all patients in dose escalation and expansion with or without documented genetic alterations in FGFR depending upon dose expansion cohort (either local or central determination)
• • Measurable disease defined by RECIST v1.1
• • ECOG performance status of ≤2
• Exclusion Criteria:
• • Prior PI3Ki or selective FGFR inhibitor treatment (for patients enrolled to expansion part)
• • Colorectal cancer (for patients enrolled to expansion part)
• • Patients with diabetes mellitus requiring insulin treatment and/or with clinical signs or with fasting glucose ≥ 140 mg/dL / 7.8 mmol/L, history of clinically significant gestational diabetes mellitus or documented steroid-induced diabetes mellitus
• • Use of medications that increase serum levels of phosphorus and/or calcium
• • Inorganic phosphorus outside of normal limits
• • Total and ionized serum calcium outside of normal limits